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Abstract
Background: Network meta-analysis is used to compare three or more treatments for the same condition. Within a
Bayesian framework, for each treatment the probability of being best, or, more general, the probability that it has a
certain rank can be derived from the posterior distributions of all treatments. The treatments can then be ranked by
the surface under the cumulative ranking curve (SUCRA). For comparing treatments in a network meta-analysis, we
propose a frequentist analogue to SUCRA which we call P-score that works without resampling.
Methods: P-scores are based solely on the point estimates and standard errors of the frequentist network
meta-analysis estimates under normality assumption and can easily be calculated as means of one-sided p-values.
They measure the mean extent of certainty that a treatment is better than the competing treatments.
Results: Using case studies of network meta-analysis in diabetes and depression, we demonstrate that the numerical
values of SUCRA and P-Score are nearly identical.
Conclusions: Ranking treatments in frequentist network meta-analysis works without resampling. Like the SUCRA
values, P-scores induce a ranking of all treatments that mostly follows that of the point estimates, but takes precision
into account. However, neither SUCRA nor P-score offer a major advantage compared to looking at credible or
confidence intervals.
Keywords: Network meta-analysis, Ranking,‘Probability of being best’-statistic, Surface under the cumulative ranking,
SUCRA, p-value, AUC
Background
An increasing number of systematic reviews use network
meta-analysis to compare three or more treatments to
each other even if they have never been compared directly
in a clinical trial [1–4]. The methodology of network
meta-analysis has developed quickly and continues to be
refined using both Bayesian and frequentist approaches.
Bayesian methods are often preferred in network meta-
analysis for their greater flexibility and more natural
interpretation. It has been argued that ‘Bayesian methods
have undergone substantially greater development’ [3, 5].
One outstanding feature of the Bayesian approach often
noted is that it allows to rank the treatments according
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to their comparative effectiveness [6–9]. From a Bayesian
perspective, parameters such as those describing the rela-
tive effectiveness of two treatments are random variables
and as such have a probability distribution. Thus state-
ments such as ‘treatment A is superior to treatment B with
probability 60 %’ or ‘Treatment A ranges under the three
best of ten treatments with probability 80 %’ are possi-
ble. By contrast, from a frequentist perspective, treatment
effects are thought as fixed parameters and thus, strictly
speaking, a concept like ‘the probability that A is better
than B’ does not make sense.
Within the Bayesian framework, authors have noted
that it is not sufficient and can be misleading to solely
look at the probability of being best, as it does not take
uncertainty into account [7–16]. Salanti et al., introduc-
ing a rank statistic, extended the consideration to the
probabilities that a treatment out of n treatments in a
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network meta-analysis is the best, the second, the third
and so on until the least effective treatment [6]. They
also introduced several graphical presentations of rank-
ing, such as rankograms, bar graphs and scatterplots
[10, 17], and a numerical summary of the rank distribu-
tion, called the Surface Under the Cumulative RAnking
curve (SUCRA) for each treatment [6, 18, 19]. WinBUGS
code for obtaining rank probabilities is given in the sup-
plementary information of [20].
Objective
In this article, we intend a critical appraisal of ranking,
considering both the Bayesian and the frequentist per-
spective. We use a simple analytical argument to show
that the probability of being best can be misleading if we
compare only two treatments. For comparing more than
two treatments, we explain the SUCRA statistic and intro-
duce a quantity, called P-score, that can be considered as
a frequentist analogue to SUCRA. We demonstrate that
the numerical values are nearly identical for a data exam-
ple. Finally we argue that both SUCRA and P-score offer
no major advantage compared to looking at credible or
confidence intervals.
Data
Our first real data example is a network of 10 diabetes
treatments including placebo with 26 studies, where the
outcome was HbA1c (glycated hemoglobin, measured as
mean change or mean post treatment value) [21]. These
data are provided with R package netmeta [22].
The second real data example is a network of 9 phar-
macological treatments of depression in primary care
with 59 studies (including 7 three-arm studies), where the
outcome was early response, measured as odds ratio
(OR) [23].
Methods
Suppose a network meta-analysis has been conducted
using Bayesian methods.We first consider two treatments
A and B. Let μA and μB be independent estimates rep-
resenting the arm-based effects of treatments A and B,
respectively, as estimated in the network meta-analysis.
Let the effects be scaled thus that higher values represent
better success. We are interested in the probability that
A is more effective than B, that is we want to compute
P(μA > μB).
Independent normally distributed posteriors
For simplicity, let us assume normal distributions for
the posteriors, precisely let μA ∼ N(μˆA, σ 2A),μB ∼
N(μˆB, σ 2B). Then the distribution of μA − μB is normal
with expectation μˆA − μˆB and variance σ 2A + σ 2B and we
have
P (μA > μB) = P (μA − μB > 0)
= 1 − 
⎛
⎜⎝− μˆA − μˆB√




⎜⎝ μˆA − μˆB√
σ 2A + σ 2B
⎞
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where  is the cumulative distribution function (cdf) of
the standard normal distribution. It follows that P(μA >






σ 2A + σ 2B
)
>
0.5, which is true if and only if μˆA > μˆB, independently
of σ 2A + σ 2B . In other words, whether A or B is thought
more effective (‘better’) depends only on the sign of the
difference of the point estimates: the treatment with the
greater point estimate wins, regardless of the variances.
Fictitious example
Figure 1 shows a fictitious example of two independent
normal distributions with means 0.5 and 0 and variances
4 and 1 for treatments A and B, respectively. The theo-
retical 95 % credible interval of the broader distribution
of treatment A (-3.42 to 4.42) completely covers that of
the narrower distribution of treatment B (-1.96 to 1.96,
dashed). It is natural to conclude that there is no evidence
of a difference between the treatments in effectiveness,
particularly due to the lack of precision in estimating the
effect of A. Note that the densities are cutting each other
at two different points: there are regions both to the right
and to the left hand side where the density of the flat
distribution (treatment A) is greater than that of the dis-
tribution of B. In these regions the flat distribution has
more mass than the precise distribution, just because it is
flat. That is, particularly there is a high probability that A
creates unfavorable effects less than −2, that are unlikely
to occur under treatment B. Nevertheless, the probability
that A is better than B is computed as (0.5/
√
5) = 0.59.
Since this is greater than 0.5, A is thought better than B.
ROC curve
The probability P(μA > μB) can be interpreted as the
area under the curve (AUC) for the receiver operating
characteristic (ROC) curve defined by
R(t) = 1 − FA(F−1B (1 − t))
where FA, FB are the cdfs of the posterior distributions of
μA and μB (see Additional file 1 for details). In the diag-
nostic accuracy setting, the AUC provides the probability
that, given a randomly selected pair of a diseased and a
non-diseased individual, the values of the diseased and the
non-diseased individual are in the correct order, e.g., the
value of the diseased individual is greater, if higher values
indicate illness.
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Fig. 1 Fictitious example. Two normal posterior distributions
following N(0,1) (dashed) and N(0.5,22) (continuous) with credible
intervals. The probability that treatment A, corresponding to the flat
distribution, is better than treatment B, corresponding to the steep
distribution, is 59 %
For Bayesian posterior distributions, the AUC provides
the probability that, given that treatment A is truly more
effective than treatment B andwe randomly select a pair of
effect estimates for treatment A and treatment B, A proves
better than B. Figure 2 shows the ROC curve and the AUC
for the fictitious example. The large difference in variances
Fig. 2 Fictitious example: ROC curve. ROC curve and area under the
curve (AUC) corresponding to the example of Fig. 1 (AUC = 0.59)
is reflected by the asymmetric appearance of the curve.
Moreover, the curve cuts the dotted line, which is due to
the above-mentioned region to the left of Fig. 1 where we
observe more unfavorable effects occurring under A. The
AUC is 59 %. If this ROC curve would occur from the dis-
tribution of a potential diagnostic marker, nobody would
trust a diagnostic test based on that marker.
We have seen for normal posterior distributions that
the treatment with the more favorable point estimate will
be ranked first, regardless of the difference that might be
quite small, independently of the variances. If only looking
at the ranks, we inevitably ignore the potential difference
in precision and length of credible intervals between both
posterior distributions.
Comparing more than two treatments
We now consider a network meta-analysis with n treat-
ments and Bayesian posteriors μi with means μˆi (i =
1, . . . , n). We cannot assume that the μi are independent,
as they are all informed by the whole network. We have,
however, still an estimate for each difference μˆi − μˆj with
standard deviation σij. Again assuming normality for the
posteriors, we see as above






where  is the cdf of the standard normal distribution. It
follows that the order induced to all treatments by pair-
wise comparing two treatments preserves the order of the
means, independently of the variances. However, the vari-
ances enter the above equation and trigger the distance
between the underlying probabilities P(μi > μj): the
greater the variances compared to the difference, themore
the argument in (1) tends to zero and the more P(μi > μj)
tends to 0.5.
Surface under the cumulative ranking (SUCRA)
We here recapitulate the definition and interpretation of
the SUCRA probabilities introduced by Salanti et al. [6].
First, based on the Bayesian posterior distributions, for
each treatment i(i = 1, . . . , n) the probability P(i, k) that
treatment i has rank k(k = 1, . . . , n) is computed. For
each treatment i, these rank probabilities form a discrete
distribution, as
∑n
k=1 P(i, k) = 1. The cdfs for these





(r = 1, . . . , n). F(i, r) gives the probability that treatment
i has rank r or better and we have F(i, n) = 1 for all
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i. The surface under the cumulative ranking distribution
function for treatment i is then defined by




To give an interpretation of SUCRA(i), we remember
that the expectation of a discrete non-negative random
variable with values 1, . . . , n can be expressed by the area
between the cdf F and 1. For the mean rank we have
therefore




= n − (n − 1)SUCRA(i)
whence we obtain
SUCRA(i) = n − E(rank(i))n − 1 .
It follows that SUCRA(i) is the inversely scaled average
rank of treatment i, scaled such that it is 1 if E(rank(i)) = 1
(that is, i always ranks first) and 0 if E(rank(i)) = n (that
is, i always ranks last) [6, 19].
SUCRA(i) can also be interpreted as the average propor-
tion of treatments worse than i.
The mean SUCRA value is 0.5.
A frequentist version of SUCRA: The P-score
We now look at equation (1) from a frequentist per-
spective. In the frequentist setting, instead of observing
Bayesian posteriors with means and standard deviations,
we suppose to have observed effect estimates, again writ-
ten μˆi, and standard errors for all pairwise differences μˆi−
μˆj, denoted sij. Again assuming normality, the equation







We give an interpretation for Pij. Apparently, (μˆi −
μˆj)/sij is the signed z-score of the contrast between treat-
ments i and j, conditioned on the standard errors. The








It represents the probability that an absolute differ-
ence of the observed size or larger occurs, given the
null-hypothesis of no difference is true. Hence we have
Pij =
{
pij/2, if μˆi ≤ μˆj
1 − pij/2, if μˆi > μˆj
Thus, Pij is one minus the one-sided p-value of rejecting
the null hypothesis μi ≤ μj in favor of μi > μj. Pij is
at least 0.5 if we observe μˆi ≥ μˆj, making it likely that
μi > μj. Pij is less than 0.5 if we observe μˆi < μˆj, which
makes it less likely that μi > μj.
We note that, as often, it seems more natural to inter-
pret P(μi > μj) in the Bayesian setting than to explain
themeaning of Pij in the frequentist context. Nevertheless,
they both result in the same decision rule: the greater Pij,
the more certain we are that μi > μj, and vice versa. Fur-
ther we note that we do not claim or need independence
of the differences μˆi − μˆj.
We may consider the means




As Pij is interpreted as the extent of certainty that μi >
μj holds, we may interpret P¯i as the mean extent of cer-
tainty that μi is greater than any other μj, averaged over
all competing treatments j (j = i) with equal weights. In
other words, P¯i represents the rank of treatment i within
the given range of treatments, where 1 means theoreti-
cally best and 0 means worst. This corresponds to the
interpretation of SUCRA(i). We will call P¯i the P-score
of treatment i. P-scores can be seen as the frequentist
equivalent of SUCRA values.
From the definition of Pij it follows that Pji = 1 − Pij.
Thus the sum over all off-diagonal elements of the matrix











which is the same as the mean of all SUCRA values. In
Additional file 2 we give a formal proof that P-scores and
SUCRA values are identical if the true probabilities are
known.
Results
We analyzed both data sets with Bayesian as well as
frequentist methods. For the Bayesian analysis, we used
WinBUGS in combination with R package R2WinBUGS,
and for the frequentist analysis we used function netrank
of R package netmeta [24]. All analyses were based on the
random effects model.
Diabetes data
First, we report the analysis of the diabetes data given by
Senn [21]. The results were similar. Figure 3 shows the
results from WinBUGS as a forest plot where all treat-
ments were compared to placebo as a reference, ordered
by their medians. Lower values of HbA1c are thought
better. Figure 4 shows the corresponding results from
netmeta.
The Bayesian rank analysis is based on the probabilities
P(i, k) that treatment i is the k’th best treatment. These are
presented in Table 1. Placebo has a probability of 0 to be a
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Fig. 3 Diabetes data, analyzed with WinBUGS. Diabetes data,
analyzed with WinBUGS and ordered by treatment effects (REM =
random effects model, MCMC = Markov Chain Monte Carlo analysis
with 3 chains, 40000 iterations, 10000 burn in iterations discarded).
CI = credible interval (median and 2.5 % / 97.5 % quantiles). The
estimated common variance between studies was σ 2 = 0.1221
good treatment, but a probability of 86 % to be worst. Con-
versely, rosiglitazone has a probability of (41 + 32 + 17)%
= 90 % to be under the best three treatments. Pioglitazone
has a higher probability of being best (23 %) compared to
metformin (15 %). This is due to its slightly better point
estimate, in spite off its clearly lower precision. We have
already seen this phenomenon in our fictitious example.
However, metformin has the greater probability (15 % +
23 % + 29 % = 67 %) to be under the best three treatments,
compared to pioglitazone (23 % + 20 % + 21 % = 64 %).
For the frequentist analysis, Table 2 gives the matrix Pij
of one-sided p-values of rejecting the true null hypothesis
of non-inferiority of i compared to j in favor of the alter-
native hypothesis that the treatment in the row (i) is worse
than the treatment in the column (j). Small Pij-values
mean rejection, that is i is worse than j. For example,
we see that the values in the placebo row all are very
small, meaning that it is unlikely that placebo is better
than any of the other treatments. Conversely, the values in
Fig. 4 Diabetes data, analyzed with R package netmeta. Diabetes
data, analyzed with R package netmeta and ordered by treatment
effects (REM = random effects model, CI = confidence interval). The
estimated common between study variance was τ 2 = 0.1087
the rosiglitazone row are all greater than 0.8 except those
comparing rosiglitazone with metformin and pioglitazone
that are themost promising competitors.When compared
to each other, these two are nearly head to head (Pij = 0.5),
as expected due to their very similar point estimates.
Table 3 shows the Bayesian and frequentist point esti-
mates (see also Figs. 3 and 4), the SUCRA values and
the P-scores (obtained as row means from Table 2), the
treatments now ordered with decreasing rank. The results
confirm that the rankingmainly depends on the point esti-
mates, with the exception of metformin and pioglitazone
that change places, now accounting for the greater preci-
sion of metformin. Moreover, we see that SUCRA values
and P-scores, in addition to their corresponding interpre-
tation, also have very similar numeric values. R code for
the diabetes example is provided in function netrank of
the netmeta package, Version 0.8-0 [22].
Depression data
For the depression data [23], the Bayesian MCMC
approach (Fig. 5) and the frequentist approach (Fig. 6)
showed results slightly more different. Particularly, the
point estimates of TCA and SNRI are similar for the
Bayesian approach, but different when using our frequen-
tist approach. Accordingly, the ranking differs (Table 4):
For the Bayesian approach with SUCRA, TCA benefits
from its higher precision, for the frequentist approach (P-
score), SNRI benefits from its larger point estimate. We
attribute this difference to difference in point estimation
rather than the different ranking methods.
We analysed these data with a third approach, the fre-
quentist resampling method by White et al. [25, 26]. In
themvmeta function of Stata, rankings are constructed via
a parametric bootstrap procedure in analogy to drawing
from a Bayesian posterior distribution. For each param-
eter vector drawn from the multivariate distribution, the
treatment that ranks first is identified, and the proba-
bility of being best for each treatment is estimated by
the proportion of samples where this treatment ranks
first. SUCRA values are calculated as for the Bayesian
approach. The results for the depression data were very
similar to those of our own method. The point estimates
were identical and the SUCRA values nearly identical to
the P-Score values. This corroborates our conclusion that
both P-scores and SUCRA values are mainly driven by the
point estimates and that P-scores are a good approxima-
tion to values generated by resampling methods.
Discussion
It has been argued that ranking treatments by the proba-
bility of being best and SUCRA is an originally Bayesian
concept, and this has been claimed to be a reason to
prefer Bayesian methodology when performing network
meta-analysis [3, 7, 9]. In this article, we reassessed these
Rücker and Schwarzer BMCMedical ResearchMethodology  (2015) 15:58 Page 6 of 9
Table 1 Bayesian analysis of the diabetes data [21]. The entry in row i and column k gives the probability that treatment i is the k’th best
Rank 1 2 3 4 5 6 7 8 9 10
acar 0.04 0.04 0.06 0.14 0.23 0.25 0.15 0.07 0.02 0.00
benf 0.02 0.04 0.05 0.10 0.16 0.20 0.19 0.15 0.09 0.01
metf 0.15 0.23 0.29 0.20 0.08 0.03 0.01 0.00 0.00 0.00
migl 0.07 0.12 0.13 0.19 0.20 0.14 0.10 0.04 0.01 0.00
piog 0.23 0.20 0.21 0.16 0.09 0.06 0.02 0.01 0.00 0.00
plac 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.13 0.86
rosi 0.41 0.32 0.17 0.08 0.02 0.00 0.00 0.00 0.00 0.00
sita 0.03 0.02 0.03 0.04 0.09 0.12 0.17 0.23 0.22 0.05
sulf 0.00 0.00 0.00 0.01 0.02 0.05 0.18 0.30 0.40 0.04
vild 0.05 0.03 0.05 0.08 0.11 0.15 0.18 0.18 0.14 0.04
arguments. First, we have shown that for the normal
distribution the probability P(μA > μB) is larger than
P(μB < μA) if and only if the expectation of μA is greater
than that of μB. Though the probabilities depend on the
variances, the ranking order does not. We gave a ficti-
tious example where there was no evidence of a relevant
difference between treatments A and B. The correct inter-
pretation is that the uncertainty in estimating the effect
of A is too large to make us take the slightly better point
estimate very serious, and we should attribute this slight
superiority to the lack of precision. We compared the
situation to the diagnostic test setting, where the AUC
measures the probability that two values of a marker are
in correct order. It is known that ROC curves may become
asymmetrical with respect to the diagonal if one distri-
bution has a much greater variance than the other. In
extreme cases of one distribution with long tails in either
direction, the AUC makes no sense anymore.
Further, we introduced a frequentist analogue to
SUCRA. It is based solely on the point estimates and
standard errors of the frequentist network meta-analysis
estimates. From these, we derived P-scores that represent
means of one-sided p-values under normality assump-
tion. The P-scores have an interpretation analogous to the
SUCRA values and measure the extent of certainty that
a treatment is better than another treatment, averaged
over all competing treatments. The numerical values of
SUCRA and P-score were similar. Like the SUCRA values,
the P-scores induce a ranking of all treatments that mostly
follows that of the point estimates, but takes precision into
account.
It is important to consider the numerical values them-
selves, not only their ranks. For both our examples, there
are treatments (rosiglitazone and hypericum, respectively)
with an average probability of 89 % of being superior to a
competing treatment. These values are considerably high,
but they do not exceed 90 % or 95 %. Also in both exam-
ples, some other treatments have ranks quite similar to
each other. We have shown that the mean value of the
P-scores is always 0.5; however, the variance may vary
Table 2 Frequentist analysis of the diabetes data [21]. The entry in row i and column j gives one minus the one-sided p-value of
rejecting the null hypothesis that the treatment in the row (i) is worse than the treatment in the column (j) in favor of superiority of i
compared to j
acar benf metf migl piog plac rosi sita sulf vild
acar – 0.62 0.13 0.37 0.18 1.00 0.07 0.74 0.95 0.63
benf 0.38 – 0.11 0.28 0.13 0.99 0.05 0.64 0.80 0.53
metf 0.87 0.89 – 0.74 0.50 1.00 0.26 0.93 1.00 0.87
migl 0.63 0.72 0.26 – 0.29 1.00 0.14 0.82 0.94 0.72
piog 0.82 0.87 0.50 0.71 – 1.00 0.32 0.91 0.99 0.85
plac 0.00 0.01 0.00 0.00 0.00 – 0.00 0.05 0.04 0.02
rosi 0.93 0.95 0.74 0.86 0.68 1.00 – 0.96 1.00 0.92
sita 0.26 0.36 0.07 0.18 0.09 0.95 0.04 – 0.64 0.40
sulf 0.05 0.20 0.00 0.06 0.01 0.96 0.00 0.36 – 0.25
vild 0.37 0.47 0.13 0.28 0.15 0.98 0.08 0.60 0.75 –
Abbreviations: acar acarbose, benf benfluorex,metf metformin,miglmiglitol, piog pioglitazone, plac placebo, rosi rosiglitazone, sita sitagliptin, sulf sulfonylurea alone, vild
vildagliptin
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Table 3 Bayesian and frequentist point estimates, SUCRA values
and P-scores for the diabetes data [21]
Point estimates Ranks
Bayesian Frequentist SUCRA P-score
WinBUGS netmeta WinBUGS netmeta
rosiglitazone -1.24 -1.23 0.890 0.893
metformin -1.12 -1.13 0.780 0.782
pioglitazone -1.12 -1.13 0.773 0.775
miglitol -0.95 -0.95 0.620 0.614
acarbose -0.83 -0.84 0.520 0.520
benfluorex -0.74 -0.73 0.439 0.436
vildagliptin -0.68 -0.70 0.413 0.423
sitagliptin -0.56 -0.57 0.334 0.333
sulfonylurea -0.42 -0.42 0.213 0.210
placebo 0 0 0.018 0.014
greatly. All P-score values may just as well scatter tightly
around 50 %, indicating that all treatments are of simi-
lar efficacy. This is the case for the example of dietary
fat given in the supplement of [20], where the P-scores
for three treatments are 0.58 (diet 2), 0.51 (diet 1) and
0.41 (control). In such a case, simple ranks are likely to be
misinterpreted.
Salanti [1] criticized that ‘Presentation of results on the
basis of the statistical significance of pairwise compar-
isons, as suggested by Fadda et al. [27], may be misleading
as it overemphasizes the importance of p-values’. We have
shown that, somewhat ironically, a concept like SUCRA
that originates from a Bayesian point of view has a fre-
quentist analogue that in fact is simply based on p-values.
P-values are frequently used in a different context when
ranking very large gene lists in gene expression anal-
ysis and genome-wide association studies where very
Fig. 5 Depression data, analyzed with WinBUGS. Depression data,
analyzed with WinBUGS (REM = random effects model, MCMC =
Markov Chain Monte Carlo analysis with 3 chains, 40000 iterations,
10000 burn in iterations discarded). CI = credible interval (median and
2.5 % / 97.5 % quantiles). The estimated common between study
variance was σ 2 = 0.2011
Fig. 6 Depression data, analyzed with R package netmeta. Depression
data, analyzed with R package netmeta (REM = random effects
model, CI = confidence interval). The estimated common between
study variance was τ 2 = 0.1875
small two-sided p-values indicate different gene expres-
sion between groups of patients [28–30]. By contrast, our
approach leads to sums of one-sided p-values where large
values indicate higher-ranking treatments.
Kibret et al. in a simulation study [9] have shown
that unequal numbers of studies per comparison resulted
in biased estimates of treatment rank probabilities. The
expected rank was overestimated for treatments that were
rarely investigated and underestimated for treatments
occurring in many studies. This finding is probably due to
the differences in precision of estimates between rare and
frequent treatments.
Jansen et al. [31] mentioned the possibility to ‘approxi-
mate the results of a Bayesian analysis [. . . ] in a frequentist
setting’, but did not descibe details. One possible choice
is the mvmeta function of Stata we applied to our second
example.
With this method, a data augmentation step was neces-
sary to impute data for a chosen reference treatment for all
studies even if they did not have that treatment arm [25].
To the best of our knowledge, a simple analytical
method like ours, based on frequentist p-values and
bypassing the probabilities of being k’th best, has not been
described.
In this article, we limited our considerations to the
normality assumption, because in frequentist statistics
confidence intervals usually are based on a normal or t-
distribution assumption. In the Bayesian framework, pos-
terior distributions, though depending on prior assump-
tions, are not restricted to be normal, particularly, they
may be skew. We did not investigate the behaviour of
the ranking probabilities for skewed or other types of
distributions.
In a Bayesian context, probably the most straightfor-
ward question with respect to ranking treatments is the
probability of each treatment being best. However, the
concept is not so straightforward from the frequentist
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Table 4 Columns 2-4: Bayesian and frequentist point estimates (OR). Columns 5-7: SUCRA values based on MCMC analysis using
WinBUGS (SUCRA-1), P-scores, SUCRA values based on resampling using Stata function mvmeta (SUCRA-2) for the depression data [23]
Point estimates Ranks
Bayesian Frequentist SUCRA-1 P-score SUCRA-2
WinBUGS netmeta mvmeta WinBUGS netmeta mvmeta
Hypericum 2.03 1.99 1.99 0.897 0.894 0.895
Low-dose SARI 1.79 1.78 1.78 0.714 0.720 0.719
TCA 1.74 1.72 1.72 0.690 0.680 0.680
SNRI 1.74 1.74 1.74 0.681 0.689 0.689
SSRI 1.70 1.68 1.68 0.610 0.616 0.617
NRI 1.40 1.42 1.42 0.447 0.445 0.444
NaSSa 1.13 1.14 1.14 0.207 0.213 0.213
rMAO-A 1.05 1.05 1.05 0.157 0.152 0.152
Placebo 1 1 1 0.096 0.091 0.092
Abbreviations: SARI serotonin antagonist and reuptake inhibitor, TCA tricyclic and tetracyclic antidepressant, SNRI serotonin-noradrenaline reuptake inhibitor, SSRI selective
serotonin reuptake inhibitor, NRI noradrenaline reuptake inhibitor, NaSSa specific serotonergic antidepressant agents, rMAO-A reversible inhibitors of monoaminoxidase A
perspective. We explicitly note that here lies a differ-
ence between our approach and others: we completely
avoid to compute ranking probabilities (i.e., the probabil-
ity of being best, second-best, and so on). Because of the
dependence between all NMA estimates, this would be
difficult or even impossible without resampling methods.
We replace this by looking at all pairwise comparisons.
These are easy to implement, because independence is not
needed in the first step when computing the p-values of
the contrasts. We do not sum up independent quantities
when summing up the p-values in the second step, as they
all rely on estimation of the network as a whole. Never-
theless, it turns out that the interpretation of this sum is
quite similar to the interpretation of SUCRA: for treat-
ment i, it is the mean certainty that treatment i is better
than another treatment j. In a way, looking at all pairwise
comparisons is a trick for getting a ranking list without
asking for the probability of being k’th under n.
Ranking, however done, depends on the criteria. In both
our examples, this was the primary efficacy outcome of
the NMA. In practice there are almost always multiple
outcomes. A treatment may be best for efficacy, but worst
for safety, or best for short-term survival, but worse for
long-term survival.
Before ranking treatments, we have to choose criteria,
or we may give separate ranking lists for different out-
comes, or we may combine several criteria to a joint score.
The problem is known from diagnostic testing, where a
trade-off between sensitivity and specificity is made, e.g.,
by taking their sum (equivalent to the Youden index) or
a weighted sum with a combination of prevalence and
utilities as weights.
We distinguish two issues: the choice of the outcome
and how to rank treatments, given the outcome is fixed.
In the present paper, we only looked at the second
topic, assuming that a specific outcome has been selected
beforehand.
Conclusions
We introduced a frequentist analogue, called P-scores, to
the SUCRA concept in Bayesian network meta-analysis
methodology. Whereas Bayesian ranking is based on the
posterior distribution, P-scores are based on the fre-
quentist point estimates and their standard errors. Both
concepts, the Bayesian SUCRA and the frequentist P-
scores, allow ranking the treatments on a continuous
0-1 scale. The numerical values are similar. We should
keep in mind that, at least under normality assumption,
the order depends largely on the point estimates. Sim-
ply ranking treatments based on SUCRA or P-scores has
no major advantage compared to ranking treatments by
their point estimates. The values themselves of the P-score
should be taken into account. Precision should also be
taken into account by looking at credible intervals or con-
fidence intervals, whether one opts for ranking or not.
When reporting a network meta-analysis, we recommend
that authors should always present credible or confidence
intervals, for example in form of a forest plot comparing
all treatments to a chosen reference.
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